Partnering

Partner with a platform built for translation

Caelus works with partners to turn defined next-generation microbial strains into high-quality products for cardio-metabolic health. Our model is designed to combine Caelus’s scientific, regulatory, intellectual property, and manufacturing expertise with the product-development, market-access and commercial strengths of our partners.

What we bring

Partners can access a differentiated portfolio of defined strains, human and preclinical evidence, regulatory and quality expertise, intellectual property, process know-how, technical support and scalable ingredient supply. We aim to provide the full upstream foundation needed to develop credible, consistent products.

How we work

Our model is designed to preserve the scientific integrity, quality and consistency of each strain across applications and markets. Caelus therefore retains stewardship of the core strains, scientific evidence, intellectual property, and quality standards while giving partners the flexibility to develop products, propositions and commercial strategies suited to their markets and channels.

What we value

We look for partners who share our commitment to scientific rigour, responsible communication and product quality, and who can translate evidence into meaningful market impact. The strongest partnerships combine clear strategic fit with disciplined execution and a long-term view.

Partners

One example of our partnering model is the collaboration with Winclove Probiotics to bring A. soehngenii in products. Winclove is an established specialist in the research, development and production of evidence-based probiotic formulations. With nearly four decades of experience, Winclove combines scientific expertise with product development, manufacturing and commercial capabilities. This collaboration brings together Caelus’s next-generation microbiome platform, clinical evidence and intellectual property with Winclove’s expertise in translating microbiome science into high-quality products for the market.

Let's talk

If you would like to explore a collaboration around our platform, lead strain or follow-on portfolio, we would be pleased to hear from you.